Vectalys company

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.
Technology: Regenerative Medicine
Industry: Biotechnology, Health Care, Manufacturing, Science and Engineering
Headquarters: Toulouse, Midi-Pyrenees, France
Founded Date: 2005-01-01
Employees Number: 11-50
Funding Status: M&A
Investors Number: 5
Total Funding: €4.8M
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership